SureTrader Nadex Advertisement
Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board: 
Last Post: 2/27/2017 12:59:07 PM - Followers: 1316 - Board type: Free - Posts Today: 19

Biotech Values is a forum for discussing 
all facets of biotech investing with an emphasis
on fundamental analysis and avoiding scams.
We generally do not discuss microcap stocks.

Calendars and Compilations
Webcasts
Recent Biotech Buyouts
Buyouts of Biotech Partners
FoB Collaborations

Common Biotech-Newbie Mistakes
Biotech Holdings of Selected Institutional Investors
US Patent Expirations for Big-Selling Biologics
Biotech and Miscellaneous Acronyms

Top Twitter Feeds for Biotech Info
iHub's Greatest Hits (thru 5/09)

PostSubject
#209448  Sticky Note LJPC +82% on Statistically Significant LJPC-501 Phase 3 Titan V 02/27/17 12:59:07 PM
#209446  Sticky Note ADXS +10% on licensing deal with SELLAS Life DewDiligence 02/27/17 11:42:31 AM
#209443  Sticky Note Re: NASH market /bull and bear cases DewDiligence 02/27/17 11:29:30 AM
#209438  Sticky Note ABBV/ENTA—CHMP approves 8-week duration of Viekirax/Exviera* for treatment-naïve DewDiligence 02/27/17 11:02:54 AM
#209435  Sticky Note Look like BMY is hedging in 1st line jq1234 02/27/17 10:42:07 AM
#209317  Sticky Note Biocentury write-up on interchangeable FoBs (which mentions MNTA DewDiligence 02/22/17 11:33:38 AM
#209448   LJPC +82% on Statistically Significant LJPC-501 Phase 3 Titan V 02/27/17 12:59:07 PM
#209447   Both Cabozantinib and Ipilimumab doses are reduced from jq1234 02/27/17 12:52:06 PM
#209446   ADXS +10% on licensing deal with SELLAS Life DewDiligence 02/27/17 11:42:31 AM
#209445   [ONCS] "With the number of melanoma patients now being WorstLuck 02/27/17 11:35:10 AM
#209444   I haven't followed RPRX closely for the past DewDiligence 02/27/17 11:33:36 AM
#209443   Re: NASH market /bull and bear cases DewDiligence 02/27/17 11:29:30 AM
#209442   Thanks Dew for your responses. I'll take a Titan V 02/27/17 11:26:30 AM
#209441   Re; NASH players …players to watch out DewDiligence 02/27/17 11:23:32 AM
#209440   Re: NASH Analysts typically make their DewDiligence 02/27/17 11:17:06 AM
#209438   ABBV/ENTA—CHMP approves 8-week duration of Viekirax/Exviera* for treatment-naïve DewDiligence 02/27/17 11:02:54 AM
#209437   The Cabometyx/Opdivo/Yervoy triple would seem to be a DewDiligence 02/27/17 10:59:10 AM
#209435   Look like BMY is hedging in 1st line jq1234 02/27/17 10:42:07 AM
#209434   $TPIV - Immuno-Oncology Vaccines in Four Phase II trials 3DPrintInvestor 02/27/17 10:16:20 AM
#209433   I am far from being an absolutist or jq1234 02/27/17 10:00:45 AM
#209432   Give me one example of this happening from iwfal 02/27/17 08:25:47 AM
#209431   OWCP - pr is out: kei 02/27/17 07:46:33 AM
#209430   Oncosec Medical (ONCS) Granted FDA Fast Track Designation Titan V 02/27/17 06:21:54 AM
#209429   Amarin's Phase 3 Reduce-It study of Vascepa/statin was north40000 02/26/17 06:05:28 PM
#209428   What are some good players to watch out Titan V 02/26/17 06:00:43 PM
#209427   With new ceo at Rprx, with EU day hiwatt1959 02/26/17 05:38:41 PM
#209426   >> Just for the purposes of the thread, jq1234 02/26/17 03:41:59 PM
#209425   In May 2010, the FDA issued the sponsor iwfal 02/26/17 11:38:13 AM
#209423   Velcade: IDMC stopped trial at 3rd planned interim. "After jq1234 02/25/17 08:21:02 PM
#209422   Sutent: Yes, this was one major ODAC issue jq1234 02/25/17 07:50:13 PM
#209421   Entresto: I know for sure 3 interims planned, jq1234 02/25/17 07:43:23 PM
#209420   Re: Unplanned early stoppages for efficacy DewDiligence 02/25/17 07:23:26 PM
#209419   JNJ PR read to me like trial reached jq1234 02/25/17 06:10:28 PM
#209418   p.s. Some clinicians/KOLs oppose this kind of early iwfal 02/25/17 04:38:29 PM
#209417   Five ALDX insiders bought a cumulative $335K @$4.50/sh DewDiligence 02/25/17 04:14:51 PM
#209416   I can't remember who but wasn't there a ghmm 02/25/17 03:33:44 PM
#209415   The DSMB would have no choice but to DewDiligence 02/25/17 03:19:36 PM
#209414   Mortality rates among Chinese men aged 41-60, who DewDiligence 02/25/17 12:43:25 PM
#209413   ORPN—Preliminary prospectus for $10M offering: DewDiligence 02/25/17 10:02:31 AM
#209412   OWCP..not only they own 8 patents but also kei 02/25/17 08:59:22 AM
#209411   No notice of closing the sgyp offering does nsomniyak 02/25/17 08:42:53 AM
#209410   FGEN I guess the obvious question for me iwfal 02/24/17 10:32:00 PM
#209409   OWCP.. Current Events: We have Boca Wall Street kei 02/24/17 10:26:54 PM
#209408   FGEN - The above quote-within-a-quote (red text), implies mcbio 02/24/17 09:18:56 PM
#209407   AKAO well if U have time I'd Whalatane 02/24/17 08:29:31 PM
#209406   Thanks kei for the OWCP 8-K that is Eagle1 02/24/17 08:17:14 PM
#209405   OWCP - new 8k out after-hour kei 02/24/17 07:56:05 PM
#209404   Fortunately, MNTA does not have to worry about DewDiligence 02/24/17 07:09:48 PM
#209403   NASH Is Todd Hagopian's Top Biotech Sub-Sector For Titan V 02/24/17 06:13:49 PM
#209402   Pharma company Incyte is moving to the S&P Titan V 02/24/17 06:06:37 PM
#209401   Those not stratifying PD-L1 expression at randomization are jq1234 02/24/17 05:03:49 PM
#209400   CLSD up 17% on higher volume on no bladerunner1717 02/24/17 04:00:04 PM
#209399   AKOA / PLSE: poorgradstudent 02/24/17 03:06:04 PM
#209398   PFE sells $1.06B of 30-year bonds to Taiwanese investors: DewDiligence 02/24/17 02:10:11 PM
#209397   Thx Peter dewophile 02/24/17 01:53:19 PM
#209396   ORPN had $9.9M of cash at 12/31/16—a burn DewDiligence 02/24/17 12:39:18 PM
PostSubject